金石亚药(300434) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥291,494,123.06, a decrease of 19.65% compared to ¥362,785,115.79 in the same period last year[7] - Net profit attributable to shareholders was ¥62,851,306.76, down 30.02% from ¥89,816,224.68 year-on-year[7] - Basic and diluted earnings per share decreased by 30.05% to ¥0.1564 from ¥0.2236 in the previous year[7] - Total operating revenue decreased to ¥291,494,123.06 from ¥362,785,115.79, representing a decline of approximately 19.6% year-over-year[19] - Net profit for the period was ¥62,093,800.87, down from ¥89,543,650.31, reflecting a decline of approximately 30.7% year-over-year[20] - Total comprehensive income for the period was 62,093,800.87, compared to 89,543,650.31 in the previous period, reflecting a decrease of approximately 30.7%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to -¥11,901,035.41, compared to -¥90,480,979.33 in the previous year, marking an 86.85% reduction in cash outflow[7] - Cash inflow from operating activities totaled 243,440,432.22, down from 269,417,067.00, indicating a decrease of approximately 9.6%[22] - Cash outflow from operating activities was 255,341,467.63, compared to 359,898,046.33, showing a reduction of about 29%[22] - Cash and cash equivalents decreased to ¥278,144,896.95 from ¥417,291,861.81, a reduction of about 33.4%[15] - Cash and cash equivalents at the end of the period were 278,144,896.95, down from 444,143,577.19, a decrease of approximately 37.4%[23] - The company reported a net decrease in cash and cash equivalents of -139,146,964.86, compared to -101,755,349.77 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,982,408,822.63, a decrease of 2.37% from ¥3,054,853,621.61 at the end of the previous year[7] - Total assets decreased to ¥2,982,408,822.63 from ¥3,054,853,621.61, a decline of about 2.4%[17] - Total liabilities decreased to ¥449,880,943.38 from ¥585,319,543.23, a reduction of approximately 23.1%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,993[13] - The top shareholder, Gao Yaping, holds 25.11% of the shares, totaling 100,878,929 shares[13] Operational Efficiency - Total operating costs reduced to ¥220,668,215.68 from ¥247,274,368.45, a decrease of about 10.8% year-over-year[19] - The company reported a significant increase in research and development expenses to ¥11,012,429.64 from ¥8,503,028.08, an increase of about 29.0% year-over-year[19] Non-Recurring Items - The company reported non-recurring gains of ¥5,121,029.49, primarily from government subsidies and asset disposals[8] Other Observations - The decline in revenue and net profit was attributed to intensified market competition in the cold medicine sector and adjustments in the company's sales structure[11] - The first quarter report was not audited, indicating a need for further scrutiny of financial results[24]